scholarly journals How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation

Transfusion ◽  
2018 ◽  
Vol 58 (11) ◽  
pp. 2483-2489 ◽  
Author(s):  
Elizabeth S. Allen ◽  
Randin C. Nelson ◽  
Willy A. Flegel
Keyword(s):  
Sickle Cell Disease ◽  
Blood Cell ◽  
Cell Transplantation ◽  
Sickle Cell ◽  
Red Blood Cell ◽  
Progenitor Cell ◽  
Hematopoietic Progenitor Cell ◽  
Cell Disease ◽  
Hematopoietic Progenitor ◽  
Cell Compatibility

Red blood cell fragmentation before hematopoietic progenitor cell transplantation

Transfusion ◽  
2004 ◽  
Vol 44 (12) ◽  
pp. 1791-1793 ◽  
Author(s):  
Shion Imoto ◽  
Tohru Murayama ◽  
Keiichiro Kawasaki ◽  
Yasuyo Okumachi ◽  
Katsuyasu Saigo ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cell Transplantation ◽  
Red Blood Cell ◽  
Progenitor Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor

Immunohematologic Complications after Nonmyeloablative Hematopoietic Progenitor Cell Transplantation in Patients with Sickle Cell Disease

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3404-3404
Author(s):  
Elizabeth S. Allen ◽  
Matthew M. Hsieh ◽  
Courtney D. Fitzhugh ◽  
Harvey G. Klein ◽  
John F. Tisdale ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Progenitor Cell ◽  
Conditioning Regimen ◽  
Red Cells ◽  
Hematopoietic Progenitor Cell ◽  
Clinical Effects ◽  
Red Cell ◽  
Cell Disease ◽  
Hematopoietic Progenitor

Abstract Abstract Background: Hematopoietic progenitor cell (HPC) transplantation can cure sickle cell disease (SCD). Anonmyeloablative conditioning regimen has lower morbidity and mortality, and typically results in donor-derived erythrocytes and stable mixedchimerism of recipient- and donor-derived leukocytes. There is a risk ofimmunohematologic complications due to red cell antibodies induced by transfusions during theperi-transplantation period or exposure to donor antigens from the HPC graft. We described the incidence ofimmunohematologic complications in a cohort of patients with SCD undergoing HPC transplantation. Study design and methods: All patients with SCD (42 with HLA-matched and 19 withhaploidentical donors) enrolled in 3 clinical trials before March 31, 2015, were retrospectively evaluated for the formation of new red cell antibodies after transplantation or any red cell incompatibility between donor and recipient. Results: Of the 61 patients, 9 experienced immunohematologic complications. Before HPC transplantation, 3 patients had antibodies that were incompatible with their donors. After HPC transplantation, new antibodies were observed in 6 patients (11 allo-, 2 auto-), 3 of whom developed antibodies that were incompatible with donor or recipient red cells, while 3 developed antibodies that were compatible. The occurrence of new alloantibodies was not significantly associated with allo- or autoantibodies at enrollment, number of pre-enrollment transfusions, recipient sex, or ABO blood group. On average, the 3 patients with antibodies at enrollment that were incompatible with donor red cells received more red cell transfusions and depended on transfusion for longer time periods than comparison groups (51 vs. 13 units, p=0.015; 419 vs. 38 days, p=0.009). Among the 9 patients withimmunohematologic complications, the clinical course was highly variable: some had no significant effects attributable to the antibodies, while others experienced prolongedreticulocytopenia, severe anemia, or became almostuntransfusable. In the 47 patients who maintained their grafts long-term,immunohematologic complications did not negatively impact hemoglobin concentration or hemoglobin S expression after transfusion independence. There was no significant correlation betweenimmunohematologic complications and graft failure, rejection or death. Conclusions:Immunohematologic complications occurred in 15% of patients with SCD undergoingnonmyeloablative HPC transplantation. Clinical effects ranged from seemingly insignificant to potentially fatal. The formation of new antibodies was not predictable. In individuals with SCD, careful evaluation of donor and recipient phenotypes using red cell genotyping aids in preventing and managingimmunohematologic complications. Disclosures No relevant conflicts of interest to declare.

scholarly journals Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 811
Author(s):  
Camille Boisson ◽  
Minke A. E. Rab ◽  
Elie Nader ◽  
Céline Renoux ◽  
Celeste Kanne ◽  
...  
Keyword(s):  
Steady State ◽  
Sickle Cell Disease ◽  
Blood Cell ◽  
Sickle Cell ◽  
Red Blood Cell ◽  
Cell Disease ◽  
Oxygen Gradient ◽  
Acute Complication ◽  
Adults And Children ◽  
The Difference

(1) Background: The aim of the present study was to compare oxygen gradient ektacytometry parameters between sickle cell patients of different genotypes (SS, SC, and S/β+) or under different treatments (hydroxyurea or chronic red blood cell exchange). (2) Methods: Oxygen gradient ektacytometry was performed in 167 adults and children at steady state. In addition, five SS patients had oxygenscan measurements at steady state and during an acute complication requiring hospitalization. (3) Results: Red blood cell (RBC) deformability upon deoxygenation (EImin) and in normoxia (EImax) was increased, and the susceptibility of RBC to sickle upon deoxygenation was decreased in SC patients when compared to untreated SS patients older than 5 years old. SS patients under chronic red blood cell exchange had higher EImin and EImax and lower susceptibility of RBC to sickle upon deoxygenation compared to untreated SS patients, SS patients younger than 5 years old, and hydroxyurea-treated SS and SC patients. The susceptibility of RBC to sickle upon deoxygenation was increased in the five SS patients during acute complication compared to steady state, although the difference between steady state and acute complication was variable from one patient to another. (4) Conclusions: The present study demonstrates that oxygen gradient ektacytometry parameters are affected by sickle cell disease (SCD) genotype and treatment.

Microfluidic electrical impedance assessment of red blood cell mediated microvascular occlusion

Lab on a Chip ◽  
2021 ◽  
Author(s):  
Yuncheng Man ◽  
Debnath Maji ◽  
Ran An ◽  
Sanjay Ahuja ◽  
Jane A Little ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Blood Cell ◽  
Red Blood Cells ◽  
Sickle Cell ◽  
Red Blood Cell ◽  
Blood Cells ◽  
Electrical Impedance ◽  
Cell Disease ◽  
Blood Disorders

Alterations in the deformability of red blood cells (RBCs), occurring in hemolytic blood disorders such as sickle cell disease (SCD), contributes to vaso-occlusion and disease pathophysiology. However, there are few...

Red Blood Cell Folate and Serum Vitamin B12 Status in Children With Sickle Cell Disease

2001 ◽  
Vol 23 (3) ◽  
pp. 165-169 ◽  
Author(s):  
Tay S. Kennedy ◽  
Ellen B. Fung ◽  
Deborah A. Kawchak ◽  
Babette S. Zemel ◽  
Kwaku Ohene-Frempong ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Blood Cell ◽  
Vitamin B12 ◽  
Sickle Cell ◽  
Red Blood Cell ◽  
Serum Vitamin ◽  
Cell Disease
Sign in / Sign up

Export Citation Format

Share Document